INTRODUCTION
============

After the coronavirus disease 2019 (COVID-19) in December 2019 in Wuhan, China, the first confirmed patient occurred on January 20 in Korea. And, some sporadic influx occurred mostly from abroad. However, in the middle of February, starting with patient number 31 in the Daegu region, a massive outbreak of COVID-19 occurred in that region and followed by nationwide outbreaks.[@B1]

In the case of representative influenza of respiratory diseases, it is known that chronic disease patients have a reduced immune function due to the underlying disease, which increases the susceptibility to infection that increases the risk of complications such as dysfunction of other organs and exacerbation of the underlying disease or death.[@B2] In the Wan et al study of China, 31.9% of all 135 hospitalized patients with COVID-19 had underlying disease.[@B3] The Chen et al.[@B4] study showed that 36.1% of the total 249 patients with COVID-19 had comorbidity. In addition the Jian-ya[@B5] study found that 7 out of 51 patients who were discharged were severe, and 6 of them had comorbidity.

In Korea, the mass outbreak of COVID-19 involving the worship of a religious group has become the starting point for the nationwide spread. However, the current situation of community infection is caused by various factors. Most of the deaths were classified as high-risk group, and shown to have high mortality rate when accompanied by underlying disease.[@B1] Therefore, the purpose of this study is to contribute to the establishment of effective quarantine measures by identifying comorbidities affecting deaths caused by COVID-19 and selecting high-risk groups that require preemptive precautions.

The specific purpose is as follows.

1.  1\) Identify the general characteristics of the patients and the crude death rate (CDR).

2.  2\) Present the status of history of comorbidity of the study subjects.

3.  3\) Identify epidemiological factors affecting the death of the study subjects.

4.  4\) The relationship between chronic diseases and death among the comorbidities of the study subjects is comprehensively identified.

METHODS
=======

Registry data of Korea Centers for Disease Control and Prevention (KCDC) of confirmed COVID-19 up to March 26, 2020 and the database of Korean National Health Insurance Service (KNHIS) has been linked to be used as study data.[@B1][@B6]

A total of 9,148 subjects were reported by the KCDC, 3,556 males (39.0%) and 5,592 females (61.0%) were identified. A total of 9,148 subjects in the registry data from the KCDC were linked to the NHIS DB\'s population/health insurance premium table, and workplace table to extract income level variables reflecting the residential area and insurance type. It was considered to have a history of the comorbidity if the medical statement data satisfies the conditions of hospitalization for more than three days, or outpatient visits for more than four days, or prescriptions for medicines for more than 28 days annually, between 2002 and 2019. Sex, age, and death variables were used in the registry data from the KCDC.

The χ^2^ test was used to see the difference between the general characteristics of patients diagnosed with COVID-19 and their death status in connection with the registry data from the KCDC and the NHIS\'s database, which came up with the CDR. In addition, the history of comorbidity of confirmed patients according to the classification group of 298 diseases was confirmed. Lastly, to examine the relationship between precedent chronic disease among epidemiologic factors and comorbidity, affecting death in patients who were confirmed, multivariate logistic regression analysis was performed, along with odds ratio and 95% confidence interval (CI) calculation. All analyzes were analyzed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA), and the statistical significance level was indicated to be less than *P* value 0.05.

Ethics statement
----------------

This study was exempted from deliberation by the Yonsei University Institutional Review Board (IRB) for the exemption from IRB deliberation that does not include personally identifiable information (CR320311).

RESULTS
=======

General characteristics and survey mortality rate
-------------------------------------------------

Looking at the general characteristics of the study subjects, 67 deaths were found among 3,556 males confirmed patients, and the mortality rate was 1.88% ([Table 1](#T1){ref-type="table"}). Of the 5,592 females, the death was 63, and the mortality rate was 1.13%. Looking at the age group, the highest number of confirmed patients was between 20 to 24 years old and 1,352 patients, followed by 25 to 29 years old. The number of deaths was as high as 32 from age 75 to 79, and the mortality rate was high at 14.22% between age 80 to 84. In the case of the region, the number of confirmed patients was the highest in Daegu with 6,454 patients, and the number of deaths was also high. At the lowest level of employee, the number of confirmed patients was the highest with 1,518, and the number of deaths was 26 among the population with Medicaid Service.

###### General characteristics in the study population
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  Variables                        Confirmed group   Mortality group   CDR, %   *P* value              
  -------------------------------- ----------------- ----------------- -------- ----------- ---------- -------
  Total                            9,148             130               1.42                            
                                   Sex                                                                 
                                                     Male              3,556    67          1.88       0.003
                                                     Female            5,592    63          1.13       
  Age group, yr                                                                                        
                                   0--4              46                                     \< 0.001   
                                   5--9              57                                                
                                   10--14            126                                               
                                   15--19            353                                               
                                   20--24            1,352                                             
                                   25--29            1,126                                             
                                   30--34            457                                               
                                   35--39            485               1        0.21                   
                                   40--44            498               1        0.20                   
                                   45--49            739                                               
                                   50--54            906               3        0.33                   
                                   55--59            819               7        0.85                   
                                   60--64            710               9        1.27                   
                                   65--69            445               10       2.25                   
                                   70--74            318               9        2.83                   
                                   75--79            296               32       10.81                  
                                   80--84            204               29       14.22                  
                                   ≥ 85              211               29       13.74                  
  Nationwide                                                                                           
                                   Seoul             355                                    0.167      
                                   Busan             112               2        1.79                   
                                   Daegu             6,454             93       1.44                   
                                   Incheon           39                                                
                                   Gwangju           19                                                
                                   Daejeon           30                                                
                                   Ulsan             36                                                
                                   Sejong            44                                                
                                   Gyeonggi          399               4        1.00                   
                                   Gangwon           30                1        3.33                   
                                   Chungbuk          39                                                
                                   Chungnam          124                                               
                                   Jeonbuk           10                                                
                                   Jeonnam           8                                                 
                                   Gyeongbuk         1,262             30       2.38                   
                                   Gyeongnam         90                                                
                                   Jeju              6                                                 
                                   Airport           91                                                
  Health insurance premium level                                                                       
                                   Medicaid          727               26       3.58        \< 0.001   
  Self-employed                                                                                        
                                   Lowest            661               8        1.21                   
                                   Low               454               4        0.88                   
                                   Middle            469               7        1.49                   
                                   High              424               6        1.42                   
                                   Highest           392               12       3.06                   
  Employee                                                                                             
                                   Lowest            1,518             18       1.19                   
                                   Low               1,442             12       0.83                   
                                   Middle            1,189             13       1.09                   
                                   High              934               12       1.28                   
                                   Highest           938               12       1.28                   

CDR = crude death rate.

Status of history of comorbidity
--------------------------------

Looking at the history of comorbidities in patients with COVID-19, other disorders of the teeth and supporting structures were the highest at 70.4%, followed by acute bronchitis and acute bronchiolitis 53.5%, gastritis and duodenitis 53.2%, 52.1% of other nose and nasal sinuses, and 50.2% of other acute upper respiratory infections ([Table 2](#T2){ref-type="table"}). Among comorbidities, in case of chronic disease, essential hypertension was 17.6%, asthma 16.9%, bronchitis, emphysema and other chronic obstructive pulmonary diseases 13.8%, rheumatoid arthritis and other inflammatory polyarthropathies were 12.2% and diabetes mellitus 9.9%.

###### History of comorbidities^a^ in the study population
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  Number   Classification of 298 diseases                                                       Values
  -------- ------------------------------------------------------------------------------------ --------------
  1        Other disorders of teeth and supporting structures                                   6,438 (70.4)
  2        Acute bronchitis and acute bronchiolitis                                             4,894 (53.5)
  3        Gastritis and duodenitis                                                             4,870 (53.2)
  4        Other diseases of nose and nasal sinuses                                             4,768 (52.1)
  5        Other acute upper respiratory infections                                             4,593 (50.2)
  6        Acute pharyngitis and acute tonsillitis                                              4,358 (47.6)
  7        Other diseases of the skin and subcutaneous tissue                                   4,054 (44.3)
  8        Soft tissue disorders                                                                3,812 (41.7)
  9        Dislocations, sprains and strains of specified and multiple body regions             3,444 (37.6)
  10       Other dorsopathies                                                                   3,149 (34.4)
  11       Other symptoms, signs and abnormal clinical and laboratory findings, NEC             3,038 (33.2)
  12       Other injuries of specified, unspecified and multiple body regions                   3,037 (33.2)
  13       Other diseases of esophagus, stomach and duodenum                                    3,009 (32.9)
  14       Dental caries                                                                        2,468 (27.0)
  15       Other diseases of intestines and peritoneum                                          2,346 (25.6)
  16       Arthrosis                                                                            1,900 (20.8)
  17       Acute laryngitis and tracheitis                                                      1,885 (20.6)
  18       Infections of the skin and subcutaneous                                              1,827 (20.0)
  19       Cervical and other intervertebral disc disorders                                     1,780 (19.5)
  20       Mycoses                                                                              1,653 (18.1)
  21       Fractures of other limb                                                              1,649 (18.0)
  22       Conjunctivitis and other disorders of conjunctiva                                    1,641 (17.9)
  23       Other endocrine, nutritional and metabolic disorders                                 1,631 (17.8)
  24       Essential(primary) hypertention                                                      1,610 (17.6)
  25       Asthma                                                                               1,549 (16.9)
  26       Other disorders of joints                                                            1,540 (16.8)
  27       Other diseases of the eye and adnexa                                                 1,511 (16.5)
  28       Acute rheumatic fever                                                                1,452 (15.9)
  29       Gastric and duodenal ulcer                                                           1,441 (15.8)
  30       Chronic sinusitis                                                                    1,404 (15.3)
  31       Bronchitis, emphysema and other chronic obstructive pulmonary diseases               1,259 (13.8)
  32       Otitis media and other disorders of middle ear and mastoid                           1,256 (13.7)
  33       Other inflammatory diseases of female pelvic organs                                  1,213 (13.3)
  34       Rheumatoid arthritis and other inflammatory polyarthropathies                        1,112 (12.2)
  35       Pneumonia                                                                            1,096 (12.0)
  36       Other gastroenteritis and colitis of infectious and unspecified origin               958 (10.5)
  37       Neurotic stress-related and somatoform disorders                                     947 (10.4)
  38       Diabetes mellitus                                                                    909 (9.9)
  39       Other diseases of the urinary system                                                 900 (9.8)
  40       Other diseases of upper respiratory tract                                            896 (9.8)
  41       Keratitis and other disorder of sclera and cornea                                    892 (9.8)
  42       Other diseases of the nervous system                                                 845 (9.2)
  43       Mood \[affective\] disorders                                                         779 (8.5)
  44       Cystitis                                                                             776 (8.5)
  45       Antenatal screening and other supervision of pregnancy                               746 (8.2)
  46       Other diseases of liver                                                              717 (7.8)
  47       Nerve, nerve root and plexus disorders                                               716 (7.8)
  48       Disorders of bone density and structure                                              716 (7.8)
  49       Cataract and other disorders of lens                                                 708 (7.7)
  50       Burns and corrosions                                                                 661 (7.2)
  51       Varicella and zoster                                                                 642 (7.0)
  52       Other viral diseases                                                                 637 (7.0)
  53       Abdominal and pelvic pain                                                            635 (6.9)
  54       Other mental and behavioural disorders                                               623 (6.8)
  55       encountering health services for other reasons                                       618 (6.8)
  56       Other complications of pregnancy and delivery                                        597 (6.5)
  57       Migraine and other headache syndromes                                                580 (6.3)
  58       Inflammation of eyelid                                                               561 (6.1)
  59       Other in situ and benign neoplasms and neoplasms of uncertain and unknown behavior   555 (6.1)
  60       Disorders of refraction and accommodation                                            490 (5.4)
  61       Haemorrhoids                                                                         483 (5.3)
  62       Other disorders of thyroid                                                           482 (5.3)
  63       Fracture of neck, thorax or pelvis                                                   464 (5.1)
  64       Fever of unknown origin                                                              458 (5.0)

Values are presented as number (%).

NEC = not elsewhere classified.

More than 5% frequent disease history.

^a^Annual primary or additional diagnosis: 3 days or more hospitalization, more than 4 outpatient visits, 28 days or more prescription days.

Epidemiological factors affecting the death of the study subjects
-----------------------------------------------------------------

According to epidemiologic factors affecting death in patients with COVID-19, the odds ratio of death increased as age increased from age 0--49 ([Table 3](#T3){ref-type="table"}). By the type region, the odds ratio of death was 1.73-fold (95% CI, 0.91--3.30) higher in small and medium-sized urban, 1.90-fold (95% CI, 1.15--3.16) higher in rural compared to large urban. In addition, the odds ratio of death was 1.50-fold (95% CI, 0.91--2.48) higher in the Daegu where massive outbreak occurred compared to the other regions, but was not statistically significant. By the income level reflecting the insurance type, odds ratio was found to be 2.81-fold higher (95% CI, 1.35--5.83) higher in patients with Medicaid Service than the employee with highest income level.

###### Epidemiological factors affecting mortality in the study population
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  Variables                        Mortality vs. confirmed adjusted OR (95% CI)^a^   
  -------------------------------- ------------------------------------------------- --------------------------
  Sex                                                                                
                                   Male                                              2.18 (1.50--3.17)
                                   Female                                            Ref
  Age group, yr                                                                      
                                   0--49                                             Ref
                                   50--64                                            20.32 (4.72--87.59)
                                   65--74                                            61.28 (14.20--264.40)
                                   ≥ 75                                              377.35 (92.30--1,542.80)
  District                                                                           
                                   Large urban                                       Ref
                                   Small urban                                       1.73 (0.91--3.30)
                                   Rural                                             1.90 (1.15--3.16)
  High epidemic region^b^                                                            
                                   No                                                Ref
                                   Yes                                               1.50 (0.91--2.48)
  Health insurance premium level                                                     
                                   Medicaid                                          2.81 (1.35--5.83)
  Self-employed                                                                      
                                   Lowest                                            1.19 (0.46--3.05)
                                   Low                                               1.25 (0.38--4.15)
                                   Middle                                            1.63 (0.61--4.39)
                                   High                                              1.66 (0.59--4.69)
                                   Highest                                           2.31 (0.98--5.46)
  Employee                                                                           
                                   Lowest                                            1.60 (0.74--3.47)
                                   Low                                               1.33 (0.58--3.10)
                                   Middle                                            1.34 (0.58--3.07)
                                   High                                              1.10 (0.48--2.56)
                                   Highest                                           Ref

OR = odds ratio, CI = confidence interval.

^a^Adjusted OR and 95% CI for sex, age, district, high epidemic region, health insurance premium level; ^b^Daegu region between February and March 2020.

Relationship between chronic disease and death
----------------------------------------------

Adjusting the epidemiological factors and looking at the association between comorbidities and death, when patients with COVID-19 have comorbidity the odds ratio of death by sepsis was the highest with 3.60-fold (95% CI, 1.21--10.68), acute laryngitis and tracheitis were 1.71-fold (95% CI, 1.15--2.56), influenza was 2.25-fold (95% CI, 1.17--4.34), and pneumonia was 2.29-fold (95% CI, 1.53--3.44) ([Table 4](#T4){ref-type="table"}). In the relationship between chronic comorbidities and death, the odds ratio of death with malignant neoplasm of prostate is 2.88-fold (95% CI, 1.01--8.22), hemorrhagic conditions and other diseases of the blood and blood-forming organs are 3.88-fold (95% CI, 1.52--9.88), diabetes mellitus 1.82-fold (95% CI, 1.25--2.67), acute myocardial infarction 2.38-fold (95% CI, 1.03--5.49), other ischemic heart disease 1.71-fold (95% CI, 1.09--2.66), heart failure was 3.17-fold (95% CI, 1.88--5.34), and renal failure was 3.07-fold (95% CI, 1.43--6.61).

###### Risk of mortality in the study population by comorbidities
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  Classification of 298 diseases                                               Comorbidities(−)   Comorbidities(+)   Risk of mortality        
  ---------------------------------------------------------------------------- ------------------ ------------------ ------------------- ---- --------------------
  Sepsis                                                                       8,988              125                30                  5    3.60 (1.21--10.68)
  Malignant neoplasm of prostate                                               8,999              124                19                  6    2.88 (1.01--8.22)
  Hemorrhagic conditions and other diseases of blood and bloodforming organs   8,953              123                65                  7    3.88 (1.52--9.88)
  Diabetes mellitus                                                            8,167              72                 851                 58   1.82 (1.25--2.67)
  Other endocrine, nutritional and metabolic disorders                         7,452              65                 1,566               65   1.47 (1.01--2.14)
  Schizophrenia schizotypal and delusional disorders                           8,797              120                221                 10   2.25 (1.06--4.77)
  Nerve, nerve root and plexus disorders                                       8,339              93                 679                 37   1.72 (1.13--2.64)
  Cataract and other disorders of lens                                         8,377              63                 641                 67   1.68 (1.11--2.55)
  Acute myocardial infarction                                                  8,963              122                55                  8    2.38 (1.03--5.49)
  Other ischemic heart diseases                                                8,680              98                 338                 32   1.71 (1.09--2.66)
  Heart failure                                                                8,894              105                124                 25   3.17 (1.88--5.34)
  Acute laryngitis and tracheitis                                              7,175              88                 1,843               42   1.71 (1.15--2.56)
  Influenza                                                                    8,750              117                268                 13   2.25 (1.17--4.34)
  Pneumonia                                                                    7,969              83                 1,049               47   2.29 (1.53--3.44)
  Chronic disease of tonsils and adenoids                                      8,785              125                233                 5    3.26 (1.15--9.24)
  Arthrosis                                                                    7,205              43                 1,813               87   1.59 (1.05--2.43)
  Renal tubulo-interstitial diseases                                           8,756              114                262                 16   2.48 (1.36--4.53)
  Renal failure                                                                8,956              120                62                  10   3.07 (1.43--6.61)
  Other diseases of the urinary system                                         8,162              86                 856                 44   1.55 (1.04--2.32)
  Fracture of neck, thorax or pelvis                                           8,590              94                 428                 36   1.66 (1.07--2.59)
  Essential hypertension                                                       7,492              46                 1,526               84   1.32 (0.88--1.99)

Data are presented as number.

OR = odds ratio, CI = confidence interval.

^a^Adjusted OR and 95% CI for sex, age, type of distiricts, high epidemic region and socio-economic status as shown in [Tables 1](#T1){ref-type="table"} and [3](#T3){ref-type="table"}.

DISCUSSION
==========

In the current state, it is possible to confirm the high mortality rate when aged over 65 classified as a high risk group and accompanying underlying diseases are accompanied.[@B1] Even though, 71.79% of patients with COVID-19 occurred in the Daegu region, the death rate was not significantly different compared to other regions. This may be related to Korea\'s preemptive intervention strategy of early diagnosis, tracking and action.

The main purpose of this study was to report the relationship between chronic comorbidities and death by correcting the epidemiological factors of patients with COVID-19 in Korea by linking the KNHIS\'s database with the registry data from the KCDC. According to the history of comorbidities, there include 17.6% of essential hypertension, 16.9% of asthma, 13.8% of bronchitis, emphysema and other chronic obstructive pulmonary diseases, 12.2% of rheumatoid arthritis and other inflammatory polyarthropathies, and 9.9% of diabetes. According to the results of multivariate logistic regression analysis adjusted by sex, age, type of distiricts, high epidemic region and socio-economic status, the odds ratio of dying with hemorrhagic conditions and other diseases of the blood and blood-forming organs was 3.88-fold (95% CI, 1.52--9.88), and heart failure was 3.17-fold (95% CI, 1.88--5.34), renal failure 3.07-fold (95% CI, 1.43--6.61), malignant neoplasm of prostate 2.88-fold (95% CI, 1.01--8.22), acute myocardial infarction 2.38-fold (95% CI, 1.03--5.49), diabetes mellitus was 1.82-fold (95% CI, 1.25--2.67), and other ischemic heart disease 1.71-fold (95% CI, 1.09--2.66). Even though, odds ratio of dying with essential hypertension was 1.32-fold, but was not statistically significant (95% CI, 0.88--1.99) in this nationwide study.

In the Yang et al.[@B7] study, a systematic literature review and meta-analysis of the prevalence of comorbidities in patients with COVID-19, the prevalence of comorbidities was evaluated to be high in hypertension and diabetes, and it was suggested that underlying diseases such as hypertension, respiratory disease, and cardiovascular disease could be risk factors for severe patients. Also Rodriguez-Morales et al.[@B8] systematic literature review and meta-analysis study showed that the prevalence of comorbidities in patients confirmed with COVID-19 was 36.8%, especially the highest in hypertension, followed by cardiovascular disease and diabetes. It was concluded that infection with COVID-19 was associated with serious morbidity, especially in patients with chronic disease. Arentz et al.[@B9] study found that 21 patients admitted to the intensive care unit accounted for 47.6% of chronic kidney disease, 42.9% of congestive heart failure, 33.3% of chronic obstructive pulmonary disease and diabetes among comorbidities. The results of the study are also consistent with prior studies in diabetes, heart diseases, respiratory diseases and kidney diseases. Hypertension also was a common comorbidity, but this was not a significant risk factor for death by adjusting critical epidemiologic factors like sex, age and income level. High mortality in older population seems due to physiological changes that come with ageing and potential underlying comorbidities, like malignant neoplasm, diabetes, heart disease, and so forth. The study also observed an increase in statistically significant odds ratio in the major disease groups common in older people.

Chronic patients are at degraded immunity function state due to underlying disease. Since patients with chronic diseases have increased sensitivity to COVID-19 infection, they are at higher risk for complications such as deterioration of underlying diseases, pneumonia, failure of other organs and sepsis, etc.; as a result, their chronic diseases may become severe, or the patients may die. These results suggest that comorbidities may be risk factors of death for patients exposed to the virus of COVID-19.[@B7]

COVID-19 is infected by exposure to the virus in various ways by the propagation route, but in the exposed environment, precedent chronic diseases are susceptible to infection by COVID-19, increasing morbidity, which is considered to be a high-risk recipient, so intensive care is necessary.[@B10]

The limitation of this study was that we used the diagnosis information in the KNHIS\'s claim data. The validity of the claimed diagnosis is a very traditional issue. However, we tried to overcome some of limitations by applying certain criteria like hospitalization for more than three days, or outpatient visits for more than four days, or prescriptions for medicines for more than 28 days annually. And, it is likely that the registration and evaluation system of KNHIS and Health Insurance Review and Assessment Service implemented over the past two decades in chronic and high cost diseases has affected the validity of the data.

This study analyzed the registry data of confirmed patients in connection with the NHIS\'s database. Among the chronic comorbidities, Hemorrhagic conditions and other diseases of the blood and blood-forming organs, heart failure, renal failure, malignant neoplasm of the prostate, acute myocardial infarction, diabetes, and, other ischemic heart diseases showed significant correlation with high mortality. We expect that the results of this study could we hope that this study could provide information on high risk groups for preemptive interventions to prevent progression to severe conditions and death. In the future, if a vaccine for COVID-19 is developed, it is expected that this study could be the basic data for recommending immunization by selecting those with chronic disease that had high risk of death, as recommended target diseases for vaccination. Lastly, it is necessary to study the effect of clinical interventions to prevent severe status or death with considerations of comorbidities in COVID-19 patients. In Korea, such research is also expected to be possible in the near future, depending on the accumulation of clinical information.
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